Symbols

CLLS

Cellectis·NASDAQ

--(--)

CLLS fundamentals

CLLS Q4 2025 Earnings

Cellectis (CLLS) released its earnings on Mar 20, 2026: revenue was 15.50M (YoY -53.34%), beat estimates; EPS was -0.225 (YoY -32.35%), missed estimates.

Revenue / YoY

15.50M

-53.34%

EPS / YoY

-0.225

-32.35%

Report date

Mar 20, 2026

CLLS Earnings Call Summary for Q4,2025

Clinical Milestones Achieved: Lasme-cel Phase I shows 100% response in target population; eti-cel Phase I demonstrates 88% overall response rate.
Financial Strength: $211M cash runway supports 2026 trials, with key partner milestones intact.
Strategic Differentiation: Allogeneic manufacturing enables rapid patient access, positioning Cellectis for off-the-shelf CAR T leadership.
Upcoming Catalysts: Q4 2026 interim analyses for lasme-cel and eti-cel, with BLA submissions in 2028-2029.

Earnings

EPS

Revenue

Revenue & Expenses

CLLS has released its 2025 Q4 earnings report, with revenue of 5.56M, reflecting a YoY change of -25.37%, and net profit of -26.32M, showing a YoY change of -544.41%. The Sankey diagram below clearly presents CLLS's revenue sources and cost distribution.

Key Indicators

Cellectis (CLLS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cellectis (CLLS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Cellectis (CLLS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Cellectis (CLLS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown